Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Dec;112(11):1666-77.
doi: 10.1172/JCI19785.

Mast cells are required for experimental oral allergen-induced diarrhea

Eric B Brandt  1 , Richard T Strait, Dan Hershko, Quan Wang, Emily E Muntel, Troy A Scribner, Nives Zimmermann, Fred D Finkelman, Marc E Rothenberg
Affiliations

Mast cells are required for experimental oral allergen-induced diarrhea

Eric B Brandt et al. J Clin Invest. 2003 Dec.

Abstract

Gastrointestinal allergic disorders represent a diverse spectrum of inflammatory diseases that are occurring with increasing incidence and severity. An essential question concerning these disorders is to determine the specific cells and mediators responsible for specific clinical manifestations. With this in mind, we developed a murine model of oral allergen-induced intestinal inflammation accompanied by strong Th2-associated humoral and cellular responses and focused on the immunopathogenesis of allergic diarrhea. Exposure of OVA/alum-sensitized mice to repeated doses of intragastric OVA induced genetically restricted, dose-dependent, acute diarrhea associated with increased intestinal permeability, eosinophilia, and mastocytosis. Mice developed limited systemic manifestations of anaphylaxis, even though they developed marked intestinal mucosal mast cell degranulation. Notably, experiments involving mast cell depletion (with anti-c-kit mAb), anti-IgE treatment, and Fc epsilon RI-deficient mice indicated a critical effector role for mast cells in mediating allergic diarrhea. Furthermore, allergic diarrhea was dependent upon synergistic signaling induced by serotonin and platelet-activating factor (PAF), but not histamine. These results demonstrate that oral allergen-induced diarrhea associated with experimental Th2 intestinal inflammation is largely mast cell, IgE, serotonin, and PAF dependent.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A murine model of allergen-induced diarrhea. (a) The time line illustrates that mice were sensitized with two OVA/alum intraperitoneal (i.p.) injections (vertical hatch mark) and subsequently treated with intragastric (i.g.) saline or OVA challenges every 2–3 days (vertical lines). (b) Diarrhea occurrence was assessed 15–45 minutes after intragastric challenges with either saline or increasing doses of OVA (2–50 mg in 250 μl of saline). (c) Diarrhea occurrence in BALB/c mice (n = 16) was compared with C57Bl/6 mice (n = 8) following ten intragastric OVA challenges (50 mg). (d) Representative photograph of the cecum and colon of BALB/c mice 60 minutes after ten intragastric saline or OVA challenges (upper and lower two samples, respectively). (e) Nonsensitized mice (n = 8) or OVA/alum–sensitized mice (n = 15) were treated with repeated doses of intragastric OVA (50 mg). Following five doses of OVA, sensitized mice were challenged with BSA (50 mg) as a control before resuming OVA challenges.
Figure 2
Figure 2
Clinical features associated with allergic diarrhea. (a) Anaphylaxis was assessed by measuring hypothermia following either five intragastric saline or OVA challenges. As a control, systemic anaphylaxis was induced in OVA/alum–sensitized mice by an i.v. OVA (100 μg) injection. Body temperatures are expressed in degrees Celsius as mean ± SEM (n = 8 mice/group). (b) Systemic anaphylaxis was also induced in OVA/alum–sensitized and saline- (n = 7) or OVA- (n = 13) intragastric challenged mice by an intravenous injection of OVA (100 μg). Death occurred only in the intragastric OVA group (11 out of 13 mice). (c) Jejunum segments were isolated 1 hour after five to six saline or OVA challenges, and intestinal permeability to HRP was measured in an Ussing chamber over a 180-minute period (mean ± SEM; n = 8 mice/group; *P = 0.0012).
Figure 3
Figure 3
Intestinal and systemic Th2 responses. (a) Jejunum samples were collected 60 minutes after two, three, or four saline or OVA challenges and analyzed by RPA for Th1/Th2 cytokine expression. The positive control (+) (see Methods) expressed IL-4, IL-10, and IFN-γ. The housekeeping gene L32 was used as a control for RNA loading. Total IgE (b), OVA-specific IgG1 (c), and IgG2a (d) plasma titers were measured following OVA or saline challenges (mean ± SEM; n = 8–11 mice/group; *P = 0.020; #P = 0.003.)
Figure 4
Figure 4
Role of eosinophils in allergic diarrhea. (a) Blood eosinophil levels in IL-5 transgenic (Tg) mice, IL-5/eotaxin-1 double-deficient mice (IL-5/Eot KO), and WT BALB/c mice were assessed 72 hours after the third saline or OVA challenge (mean ± SEM; n = 4–10 mice; *P < 0.0001; #P < 0.004; **P = 0.0035) (b) Representative jejunum section from OVA-challenged WT, IL-5 transgenic, and IL-5/eotaxin-1 double-deficient mice, immunostained with anti-MBP Ab as described in Methods (arrows indicate eosinophils; original magnification, ×125). (c) Jejunum eosinophil levels were assessed by morphometric analysis in IL-5 transgenic mice, IL-5/eotaxin-1 double-deficient mice, and WT BALB/c mice (mean ± SEM; n = 4 mice; *P < 0.05; #P = 0.005; **P = 0.004). (d) Diarrhea occurrence in IL-5 transgenic, IL-5/eotaxin-1 double-deficient, and WT control mice following saline or OVA challenges.
Figure 5
Figure 5
Mucosal mast cell responses in allergic diarrhea. (a) A scatter plot comparing the average difference in gene expression measured on the murine U74Av2 GeneChip following ten saline or OVA challenges was generated using GeneSpring software. The three lines indicate a twofold increase or twofold decrease compared with the mean. Representative, highly increased mast cell–related genes following diarrhea are indicated. (b) MMCP-1 plasma levels were measured by ELISA following saline or OVA challenges. Representative fields (original magnification, ×125) of saline-challenged (c) or OVA-challenged (d) jejunum sections illustrate chloroaces) indicated by arrows (original magnification, ×500). (e) Mucosal mast cell levels in the jejunum, ileum, and colon following three saline or OVA challenges were assessed by morphometric analysis of chloroacetate esterase–stained cells (n = 3–4 mice per group; #P < 0.0001; ##P = 0.013; *P = 0.032; **P = 0.003). (f) A kinetic analysis of mast cell recruitment to the jejunum of saline- or OVA-challenged mice (#P < 0.0005).
Figure 6
Figure 6
Absence of diarrhea in mast cell–depleted mice. (a) Following sensitization, mice were treated with a neutralizing ACK2 or a control Ab (J1.2) 24 hours before each intragastric challenge (arrows). Each vertical line represents saline or allergen challenge every 2–3 days. The efficacy of the treatment was assessed by chloroacetate esterase staining for jejunum mast cells (b) and measuring plasma MMCP-1 levels (c) 60 minutes after the fifth saline or OVA challenge in mice treated with either ACK2 or J1.2 (n = 4; #P < 0.005; *P = 0.0026). (d) Occurrence of diarrhea following five OVA challenges in control Ab (J1.2) or ACK2-treated mice. (e) Intestinal permeability to HRP was measured in an Ussing chamber over 180 minutes (mean ± SEM; n = 4 mice/group; *P = 0.01). n.d., not detected.
Figure 7
Figure 7
Allergic diarrhea is IgE mediated. Following two OVA/alum sensitizations, mice were treated with intragastric saline or OVA challenges as depicted in Figure 1a. Twenty-four hours before challenge six (arrow), mice were treated with either an Ab against (a) the low-affinity IgG receptors FcγRII/RIII (24G2) or (b) with an anti-IgE Ab (EM-95) (n = 6–8 mice; *P = 0.033). (c) Mice were treated with the EM-95 or GL117 control Ab (mean ± SEM; n = 4–6 mice), and intestinal permeability to HRP was measured in an Ussing chamber over 180 minutes. (d) Diarrhea occurrence in FcεRI KO mice and WT littermate controls following up to ten intragastric saline or OVA challenges (n = 6 and 5, respectively).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sampson HA. 9. Food allergy. J. Allergy Clin. Immunol. 2003; 111(Suppl. 2):S540–S547. - PubMed
    1. Rothenberg ME, Mishra A, Brandt EB, Hogan SP. Gastrointestinal eosinophils in health and disease. Adv. Immunol. 2001; 78:291–328. - PubMed
    1. Kweon MN, Kiyono H. Eosinophilic gastroenteritis: a problem of the mucosal immune system? Curr. Allergy Asthma Rep. 2003; 3:79–85. - PubMed
    1. Crowe SE, Perdue MH. Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology. Gastroenterology. 1992; 103:1075–1095. - PubMed
    1. Lin RY, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J. Allergy Clin. Immunol. 2000; 106:65–71. - PubMed

Publication types